Cargando…
COVID-19 therapies: do we see substantial progress?
The appearance of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its spread all over the world is the cause of the coronavirus disease 2019 (COVID-19) pandemic, which has recently resulted in almost 400 million confirmed cases and 6 million deaths, not to mention unknown long-term...
Autores principales: | Matusewicz, Lucyna, Golec, Marlena, Czogalla, Aleksander, Kuliczkowski, Kazimierz, Konka, Adam, Zembala-John, Joanna, Sikorski, Aleksander F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152818/ https://www.ncbi.nlm.nih.gov/pubmed/35641916 http://dx.doi.org/10.1186/s11658-022-00341-9 |
Ejemplares similares
-
Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges
por: Toporkiewicz, Monika, et al.
Publicado: (2015) -
Immunoliposomes with Simvastatin as a Potential Therapeutic in Treatment of Breast Cancer Cells Overexpressing HER2—An In Vitro Study
por: Matusewicz, Lucyna, et al.
Publicado: (2018) -
A new frameshift mutation of the β-spectrin gene associated with hereditary spherocytosis
por: Bogusławska, Dżamila M., et al.
Publicado: (2016) -
Building Blocks to Design Liposomal Delivery Systems
por: Juszkiewicz, Katarzyna, et al.
Publicado: (2020) -
The Antibody Response to the BNT162b2 mRNA COVID-19 Booster in Healthcare Workers: Association between the IgG Antibody Titers and Anthropometric and Body Composition Parameters
por: Golec, Marlena, et al.
Publicado: (2022)